Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01574222 · ClinicalTrials.gov registry record · Phase 1
A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01574222: Clinical Trial Phase 1 study, sponsored by VA Office of Research and Development.
NCT01574222 is a Phase 1 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01574222, a Phase 1 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the dose that the vaccine can be given safely to patients when injected directly into the lung tumor, without any serious side effects.
Interventions
- BIOLOGICAL autologous dendritic cell adenovirus CCL21 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-10-01 |
| Est. Completion | 2017-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01574222
The ClinicalTrials.gov registry entry for NCT01574222 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which autologous dendritic cell adenovirus CCL21 vaccine is the first listed.
NCT01574222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01574222 about?
NCT01574222 is a clinical study titled "A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer". The purpose of this study is to determine the dose that the vaccine can be given safely to patients when injected directly into the lung tumor, without any serious side effects.
What is the current status of trial NCT01574222?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2011-10-01. Estimated completion is 2017-03-01.
What interventions are being tested in trial NCT01574222?
The interventions under investigation include: autologous dendritic cell adenovirus CCL21 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01574222?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.